IRIS
SANTARPIA, Mariacarmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.401
NA - Nord America 5.176
AS - Asia 3.622
SA - Sud America 1.320
AF - Africa 122
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 16.657
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.049
RU - Federazione Russa 3.417
SG - Singapore 1.475
BR - Brasile 1.130
CN - Cina 963
IE - Irlanda 672
SE - Svezia 538
IT - Italia 473
HK - Hong Kong 394
VN - Vietnam 294
GB - Regno Unito 266
PL - Polonia 215
DE - Germania 203
FR - Francia 172
FI - Finlandia 148
IN - India 110
UA - Ucraina 90
BD - Bangladesh 74
AR - Argentina 60
CA - Canada 49
AT - Austria 48
ID - Indonesia 47
IQ - Iraq 44
MX - Messico 40
EC - Ecuador 38
ZA - Sudafrica 37
TR - Turchia 33
MA - Marocco 28
ES - Italia 27
JP - Giappone 24
NL - Olanda 24
CO - Colombia 23
UZ - Uzbekistan 22
BE - Belgio 21
VE - Venezuela 19
AE - Emirati Arabi Uniti 15
CL - Cile 14
PK - Pakistan 14
TN - Tunisia 14
PY - Paraguay 13
KE - Kenya 12
PE - Perù 11
CZ - Repubblica Ceca 10
GR - Grecia 10
AZ - Azerbaigian 9
DO - Repubblica Dominicana 9
IL - Israele 9
KZ - Kazakistan 9
MY - Malesia 9
SA - Arabia Saudita 9
AU - Australia 8
TH - Thailandia 8
AL - Albania 7
BG - Bulgaria 7
CR - Costa Rica 7
EE - Estonia 7
LT - Lituania 7
NP - Nepal 7
PA - Panama 7
RS - Serbia 7
UY - Uruguay 7
CI - Costa d'Avorio 6
DZ - Algeria 6
EG - Egitto 6
JO - Giordania 6
KG - Kirghizistan 6
KR - Corea 6
BO - Bolivia 5
CH - Svizzera 5
JM - Giamaica 5
OM - Oman 5
PH - Filippine 5
BY - Bielorussia 4
GT - Guatemala 4
IR - Iran 4
MD - Moldavia 3
SK - Slovacchia (Repubblica Slovacca) 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AO - Angola 2
CG - Congo 2
EU - Europa 2
GE - Georgia 2
HN - Honduras 2
HR - Croazia 2
KH - Cambogia 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
MN - Mongolia 2
MT - Malta 2
NI - Nicaragua 2
NO - Norvegia 2
PT - Portogallo 2
RO - Romania 2
SN - Senegal 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
Totale 16.636
Salva come PNG Salva come JPEG
Città #
Moscow 1.014
Ashburn 970
Singapore 773
Dublin 672
Dallas 570
Chandler 422
Hong Kong 392
Nyköping 306
San Jose 302
Beijing 287
Jacksonville 230
Warsaw 209
Messina 184
The Dalles 180
Los Angeles 153
Lancaster 144
Princeton 132
Medford 121
Lauterbourg 107
Dearborn 98
New York 98
Cambridge 92
Des Moines 91
Ho Chi Minh City 84
Ann Arbor 77
São Paulo 76
Munich 70
Hanoi 59
Redondo Beach 58
Santa Clara 48
Rio de Janeiro 47
Guangzhou 46
Rome 46
Tianjin 45
Buffalo 43
Council Bluffs 43
Turku 43
Boardman 38
Orem 37
Wilmington 37
Vienna 35
Dong Ket 32
Frankfurt am Main 29
Jakarta 28
Shenyang 28
Jinan 27
San Mateo 26
Seattle 26
Brooklyn 25
Montreal 23
Nuremberg 23
Atlanta 22
Milan 22
Pune 22
Tokyo 22
Brussels 21
Johannesburg 21
Shanghai 21
Quito 20
Denver 19
Tashkent 19
Houston 18
Belo Horizonte 17
Chennai 17
Düsseldorf 17
London 17
Baghdad 16
Curitiba 16
Brasília 15
Porto Alegre 15
Boston 14
Haiphong 14
Mumbai 14
Nanjing 14
Salvador 14
San Francisco 13
Amsterdam 12
Biên Hòa 12
Catania 12
Da Nang 12
Helsinki 12
Woodbridge 12
Zhengzhou 12
Bexley 11
Goiânia 11
Hebei 11
Hyderabad 11
Lappeenranta 11
Poplar 11
Stockholm 11
Campinas 10
Chicago 10
Dhaka 10
Guayaquil 10
Nairobi 10
Ningbo 10
Ribeirão Preto 10
Santiago 10
Shenzhen 10
São José do Rio Preto 10
Totale 9.447
Salva come PNG Salva come JPEG
Nome #
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 236
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 228
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 224
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 220
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 210
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 203
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 193
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 193
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 189
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 189
Liquid biopsy for lung cancer early detection 189
Applications of genomics in NSCLC 185
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 182
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 174
One-third of an archivial series of papillary thyroid cancer (Years 2007-2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable Tumor-node-metastasis staging 161
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 159
Immunotherapeutic Advances for NSCLC 157
Targeted drugs in small-cell lung cancer 154
Activation of viral defense signaling in cancer 154
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 153
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do 152
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer 151
Age-related genetic abnormalities: the Achilles’ heel for customizing therapy in elderly lung cancer patients 148
ADCs and TCE in SCLC Therapy: The Beginning of a New Era? 147
Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway 147
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 145
Advances in immunotherapy for treatment of lung cancer 145
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path? 143
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach 141
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 141
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 130
Liquid biopsy in non-small cell lung cancer: a comparison between different methodologies to detect somatic mutations 130
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC) 129
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 126
Adaptive Resistance Mechanisms in EGFR Mutant NSCLC 126
On the pharmacogenetics of non-small cell lung cancer treatment 123
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 122
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 121
A friendly approach to pesonalized treatment in lung adenocarcinoma. REVISTA COLOMBIANA DE HEMATOLOGÍA Y ONCOLOGÍA 118
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 117
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 117
DNA repair and mitotic checkpoint genes as potential predictors of chemotherapy response in non-small-cell lung cancer. 116
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 114
Emerging drugs for non-small-cell lung cancer. 114
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer 114
'Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research' 112
PIK3CA mutations in breast cancer: a potential marker 112
MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment 111
Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance 111
Polymorphisms in DNA repair genes modulate survival incisplatin/gemcitabine-treated non-small-cell lung cancer patients 108
PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance 108
Beyond platinum treatment for NSCLC: what does the future hold? 108
Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC 108
Rare histotypes of epithelial biliary tract tumors: A literature review 107
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014 106
Molecular characterization of synchronous sporadic colorectal carcinomas 105
Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient 105
A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma 105
Feasibility of cell-free circulating tumor DNA testing for lung cancer 105
Non-small-cell lung cancer signaling pathways, metabolism, and PD-1/PD-L1 antibodies 105
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 104
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review 103
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role 103
Usefulness of predictive tests for cancer treatment 102
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives 101
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer 101
History of extensive disease small cell lung cancer treatment: Time to raise the bar? a review of the literature 101
From the bench to the bed: individualizing treatment in non-small-cell lungcancer 100
Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story? 99
Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient 99
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. 99
Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma 98
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 96
High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data 96
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need 95
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? 95
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety 95
Immunotherapy in NSCLC: A promising and revolutionary weapon 92
Targeting MET amplification in EGFR-mutant non-small-cell lung cancer 92
Polycythemia vera and essential thrombocytemia treated with IFN-ALPHA2a: Evidence of a significant clinical activity and molecular response. 91
Human endogenous retroviruses and cancer 91
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints 91
Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement: a literature review and future perspectives 89
PIK3CA mutations in breast cancer: A potential predictive marker 89
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 88
Melanoma: oncogenic drivers and the immune system 88
Other targeted drugs in melanoma 87
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive 86
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 86
An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer 85
Implications of XPD312 in stage IIIA-B NSCLC 85
Predicting the outcome of chemotherapy for lung cancer. 85
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013 85
Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response 85
Comprehensive genomic profiling of combined small cell lung cancer 85
PIK3CA mutations: a potential predictive marker in advanced breast cancer treated with antimicrotubule-based chemotherapy. 84
Quanto sono utilizzati in Italia i farmaci biosimilari? Uno studio retrospettivo sull'uso degli agenti stimolanti l'eritropoiesi negli anni 2009-2013 83
Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database 83
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape 82
Targeting the tumor microenvironment in triple-negative breast cancer: Biological insights and therapeutic opportunities 81
Totale 12.326
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.530
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.530
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202143 0 0 0 0 0 0 0 0 0 0 0 43
2021/2022796 6 37 32 31 22 14 39 30 8 94 188 295
2022/20231.804 153 144 65 142 100 179 47 76 837 11 39 11
2023/2024551 34 75 40 41 38 132 33 28 13 29 4 84
2024/20252.932 47 31 66 145 155 110 76 646 727 204 258 467
2025/20268.960 390 562 720 713 667 1.787 1.061 1.065 1.092 478 214 211
Totale 17.082